{"id":"W3004787369","doi":"10.1200/jco.2020.38.4_suppl.491","title":"Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Cabozantinib; Hepatocellular carcinoma; Internal medicine; Regimen; Regorafenib; Ramucirumab; Population; Oncology; Cancer; Surgery; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006727689,0.0002808931,0.0004418666,0.001174755,0.0009810092,0.001037133,0.0005566457,0.0006388224,0.002202861],"category_scores_gemma":[0.001694708,0.0004153522,0.0004417036,0.002221104,0.000537142,0.0006917113,0.0006752277,0.0008568427,0.0005514948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001690616,"about_ca_system_score_gemma":0.001345241,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.06218635,"about_ca_topic_score_gemma":0.09290317,"domain_scores_codex":[0.9992602,0.0001155538,0.00007885688,0.0001890165,0.0002095621,0.0001467723],"domain_scores_gemma":[0.9986373,0.0001299872,0.0005862524,0.00008663725,0.0001855465,0.0003742352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001011731,0.00004971203,0.9988393,0.00001166763,0.00003492136,0.00005035365,0.00008321183,0.00001564089,0.00008159723,0.000007846137,0.0001679398,0.0005567463],"study_design_scores_gemma":[0.00002644952,0.00007819497,0.998909,0.00001129305,0.0000271143,0.0001927838,0.000283371,0.0001198823,0.00001912247,0.00001121152,0.0003163555,0.000005229981],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980394,0.000246415,0.00005663346,0.0000616246,0.00000571802,0.00005571892,0.001032024,0.000003517869,0.0004990387],"genre_scores_gemma":[0.9987279,0.0001106769,0.00005579608,0.00008247235,0.000009840556,0.00004152032,0.0008145825,0.00000233429,0.0001547478],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9378136,"threshold_uncertainty_score":0.1236488,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1042699116533265,"score_gpt":0.4551533919903907,"score_spread":0.3508834803370642,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}